EGFR and non-small cell lung carcinoma: Although this study evaluated budigalimab in 40 patients with NSCLC, similar to other anti-PD-1 therapies a lower response rate was observed in NSCLC patients with tumors that harbor EGFR-activating mutations and ALK rearrangements [31].